- cafead   Aug 17, 2023 at 11:52: PM
via BlueRock Therapeutics is shrinking its pipeline to afford growing clinical plans, including an upcoming phase 2 Parkinson’s disease trial, laying off 12% of the team across three sites.
article source
article source